Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6041812 | 0.75 | ALDH1A1 (0.39) | ALDH1A1KDM4EHPGDMEN1GAA | |
| SCHEMBL24120085 | 0.75 | HTR2C (0.51) | HTR2CADRB2HTR6SLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL23780213 | 0.74 | HTR2C (0.53) | HTR2CADRB2HTR6SLC18A3SIGMAR1 | |
| SCHEMBL30735827 | 0.73 | HTR6 (0.56) | HTR2CADRB2HTR6SLC18A3SIGMAR1 | |
| SCHEMBL2710242 | 0.73 | HTR2C (0.56) | HTR2CADRB2HTR6SLC18A3SIGMAR1 | |
| SCHEMBL19284708 | 0.73 | HTR6 (0.56) | HTR2CADRB2HTR6SLC18A3SIGMAR1 | |
| SCHEMBL30368566 | 0.73 | HTR2C (0.56) | HTR2CADRB2HTR6SLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL19284610 | 0.71 | HTR2C (0.56) | HTR2CADRB2HTR6SLC18A3SIGMAR1 | |
| Bromide SCHEMBL9325288 | 0.71 | HTR2C (0.55) | HTR2CADRB2HTR6SLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5374942 | 0.71 | HTR2C (0.58) | HTR2CADRB2ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335660-B2 | Isochroman compounds for treatment of CNS disorders | ELI LILLY AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| CN-1312148-C | Isochroman compounds for treatment of CNS disorders | LILLY CO ELI (US) | 2007-04-25 | — | — | CN | disclosed |
| EP-1458703-B1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | LILLY CO ELI (US) | 2007-02-28 | — | — | EP | disclosed |
| CN-1620447-A | Isochroman compounds for treatment of cns disorders | LILLY CO ELI (US) | 2005-05-25 | — | — | CN | disclosed |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | ELI LILLY AND COMPANY | 2005-01-20 | — | — | US | disclosed |
| EP-1458703-A1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | ELI LILLY AND COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053948-A1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | ELI LILLY AND COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | INA, CNR2, CNR1 | HTR2C 98/4885ADRB2 1157/4885ALDH1A1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.